Terms: = Germ cell tumor AND KEAP1, INrf2, ENSG00000079999, 9817, Q14145, MGC9454, MGC4407, MGC20887, MGC1114, MGC10630, KLHL19, KIAA0132 AND Prognosis
11 results:
1. TRIM25 promotes temozolomide resistance in glioma by regulating oxidative stress and ferroptotic cell death via the ubiquitination of keap1.
Wei J; Wang L; Zhang Y; Sun T; Zhang C; Hu Z; Zhou L; Liu X; Wan J; Ma L
Oncogene; 2023 Jun; 42(26):2103-2112. PubMed ID: 37188737
[TBL] [Abstract] [Full Text] [Related]
2. Exosomal hsa-piR1089 promotes proliferation and migration in neuroblastoma via targeting keap1.
Wang H; Shi B; Zhang X; Shen P; He Q; Yin M; Pan Y; Ma J
Pathol Res Pract; 2023 Jan; 241():154240. PubMed ID: 36436316
[TBL] [Abstract] [Full Text] [Related]
3. Apolipoprotein C1 promotes glioblastoma tumorigenesis by reducing keap1/NRF2 and CBS-regulated ferroptosis.
Zheng XJ; Chen WL; Yi J; Li W; Liu JY; Fu WQ; Ren LW; Li S; Ge BB; Yang YH; Zhang YZ; Yang H; Du GH; Wang Y; Wang JH
Acta Pharmacol Sin; 2022 Nov; 43(11):2977-2992. PubMed ID: 35581292
[TBL] [Abstract] [Full Text] [Related]
4. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8
Li Y; Shi X; Mao B; Wang L; Wu L; Li J; Jiao S
Lung Cancer; 2022 Apr; 166():161-169. PubMed ID: 35287068
[TBL] [Abstract] [Full Text] [Related]
5. HACE1-mediated NRF2 activation causes enhanced malignant phenotypes and decreased radiosensitivity of glioma cells.
Da C; Pu J; Liu Z; Wei J; Qu Y; Wu Y; Shi B; Yang J; He N; Hou P
Signal Transduct Target Ther; 2021 Nov; 6(1):399. PubMed ID: 34815381
[TBL] [Abstract] [Full Text] [Related]
6. NRF2 Enables EGFR Signaling in Melanoma cells.
Kreß JKC; Jessen C; Marquardt A; Hufnagel A; Meierjohann S
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33916908
[TBL] [Abstract] [Full Text] [Related]
7. Prevalence and prognostic value of PD-L1 expression in molecular subtypes of metastatic large cell neuroendocrine carcinoma (LCNEC).
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; Stallinga CM; Roemen GM; Speel EJM; Dingemans AC;
Lung Cancer; 2019 Apr; 130():179-186. PubMed ID: 30885341
[TBL] [Abstract] [Full Text] [Related]
8. An immunohistochemical study of NFE2L2, keap1 and 8-hydroxy-2'-deoxyguanosine and the EMT markers SNAI2, ZEB1 and TWIST1 in metastatic melanoma.
Hintsala HR; Haapasaari KM; Soini Y; Karihtala P
Histol Histopathol; 2017 Feb; 32(2):129-136. PubMed ID: 27170270
[TBL] [Abstract] [Full Text] [Related]
9. Nrf2/keap1 Pathway and Expression of Oxidative Stress Lesions 8-hydroxy-2'-deoxyguanosine and Nitrotyrosine in Melanoma.
Hintsala HR; Jokinen E; Haapasaari KM; Moza M; Ristimäki A; Soini Y; Koivunen J; Karihtala P
Anticancer Res; 2016 Apr; 36(4):1497-506. PubMed ID: 27069125
[TBL] [Abstract] [Full Text] [Related]
10. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
[TBL] [Abstract] [Full Text] [Related]
11. Trends in the clinical characteristics of patients with papillary thyroid carcinoma in Taiwan.
Lin JD; Chao TC; Sun JH; Ho C; Weng HF
Oncology; 2000 May; 58(4):280-5. PubMed ID: 10838492
[TBL] [Abstract] [Full Text] [Related]
